» Articles » PMID: 28755768

A Naturalistic Study of Predictors of Retention in Treatment Among Emerging Adults Entering First Buprenorphine Maintenance Treatment for Opioid Use Disorders

Overview
Specialty Psychiatry
Date 2017 Jul 31
PMID 28755768
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Emerging adulthood (between the ages 18-25years) has been conceptualized as a specific developmental stage based on unique psychosocial characteristics. Opioids are commonly used drugs in this population. Few studies have reported predictors of retention in buprenorphine maintenance treatment among opioid-dependent emerging adults, particularly from India. Moreover, no study has examined outcomes with opioid maintenance treatment among emerging adults in non-clinical trial, naturalistic settings. The current study aimed to assess retention in buprenorphine maintenance treatment among emerging adults in a naturalistic setting. Also, it aimed to assess the factors associated with retention in treatment among these individuals.

Methods: The current study was a retrospective cohort study conducted at a substance use disorder treatment centre in northern part of India. The patients who received buprenorphine maintenance treatment between 1st January 2012 and 31st December 2014 were eligible for inclusion in the current study. The follow-up data of these subjects were assessed up to and including 31st March 2015. Information was retrieved on socio-demographic variables. The information related to substance use included type of substance, duration of use, age of onset, motive of use, route of administration and source of procurement. Additionally, details of buprenorphine dose, dispensing pattern, induction settings were recorded. Cox regression analysis was carried out to assess the predictors of retention in buprenorphine maintenance treatment.

Results: Of 68 emerging adults, 33.8% were retained in treatment at 90days, 19.1% at 6months and 11.7% at one year. After controlling for various covariates in adjusted Cox regression analysis, substance use in first degree relatives (AHR: 2.40, 95% CI 1.33-4.31), lower daily buprenorphine dose (AHR: 0.86, 95% CI 0.78-0.94) and past month injection drug use (AHR: 0.30, 95% CI 0.14-0.66) were found to be the significant predictors of treatment dropout.

Conclusions: The findings of the current study help understand the predictors of retention in buprenorphine maintenance treatment among emerging adults in a real-world situation. These findings will help guide formulation of responsive and relevant buprenorphine maintenance treatment program for the emerging adults.

Citing Articles

Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial.

McPherson S, Smith C, Hall L, Miguel A, Bowden T, Keever A Drug Alcohol Depend. 2024; 256:111099.

PMID: 38306822 PMC: 10923156. DOI: 10.1016/j.drugalcdep.2024.111099.


Relapse during opioid use disorder treatment: A pilot study to understand the reasons for opioid use during treatment.

Singh V, Dhawan A, Sarkar S, Mishra A, Chadda R Ind Psychiatry J. 2024; 32(2):361-368.

PMID: 38161454 PMC: 10756605. DOI: 10.4103/ipj.ipj_87_22.


Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability.

Smith C, Keever A, Bowden T, Olson K, Rodin N, McDonell M JMIR Form Res. 2023; 7:e40437.

PMID: 37074780 PMC: 10157459. DOI: 10.2196/40437.


Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India.

Ganapathi L, McFall A, Greco K, Srikrishnan A, Kumar M, Mayer K Drug Alcohol Depend. 2023; 246:109839.

PMID: 37031487 PMC: 10416117. DOI: 10.1016/j.drugalcdep.2023.109839.


Assessing the feasibility, usability and acceptability of the platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial.

Janzow G, Harding C, Flores M, Borodovsky J, Steinkamp J, Marsch L Drug Alcohol Depend Rep. 2023; 3:100045.

PMID: 36845988 PMC: 9949338. DOI: 10.1016/j.dadr.2022.100045.